公开(公告)号：US20240075064A1

公开(公告)日：2024-03-07

申请号：US18261761

申请日：2022-01-18

申请人： OBSIDIAN THERAPEUTICS, INC.

发明人： Kutlu Goksu Elpek ,  Celeste Richardson ,  Michelle Lois Fleury ,  James Alex Storer ,  Shyamsundar Subramanian ,  Mithun Khattar

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/46444 ,  A61P35/00 ,  C07K14/5443 ,  C12N5/0636

摘要： The present disclosure provides compositions and methods for expanding T cells or tumor infiltrating lymphocytes (TILs) in vitro. K562 feeder cells engineered to express a costimulatory molecule (e.g., 41BB ligand (41BBL)) and either interleukin 21 (IL21) or interleukin 7 (IL7) can be used in a rapid expansion protocol (REP) step to expand the T cells or TILs. Thus, provided herein is a culture comprising T-cells or TILs and modified K562 feeder cells. The T cells can be modified to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) or the TILs can be modified to express membrane-bound IL15 (mbIL15). The T cells or TILs can be expanded in vitro using aREP without the use of exogenous interleukin 2 (IL2), and the expanded cells can be used in adoptive cell therapy for treatment of cancer without concomitant use of an exogenous cytokine such as IL2.

公开(公告)号：US20240226158A9

公开(公告)日：2024-07-11

申请号：US18501621

申请日：2023-11-03

申请人： OBSIDIAN THERAPEUTICS, INC.

发明人： Mithun Khattar ,  Shyamsundar Subramanian ,  Rachel Burga ,  Michelle Lynn Ols ,  Jan ter Meulen ,  Kyle Pedro ,  Jeremy Hatem Tchaicha

IPC分类号： A61K35/17 ,  A61P35/00 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61P35/00 ,  C12N5/0636

摘要： Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.

公开(公告)号：US20220133801A1

公开(公告)日：2022-05-05

申请号：US17577940

申请日：2022-01-18

申请人： Obsidian Therapeutics, Inc.

发明人： Mithun Khattar ,  Shyamsundar Subramanian ,  Rachel Burga ,  Michelle Lynn Ols ,  Jan ter Meulen ,  Kyle Pedro ,  Jeremy Hatem Tchaicha

IPC分类号： A61K35/17 ,  C12N5/0783 ,  A61P35/00

摘要： Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.

公开(公告)号：US20240131069A1

公开(公告)日：2024-04-25

申请号：US18501621

申请日：2023-11-02

申请人： OBSIDIAN THERAPEUTICS, INC.

发明人： Mithun Khattar ,  Shyamsundar Subramanian ,  Rachel Burga ,  Michelle Lynn Ols ,  Jan ter Meulen ,  Kyle Pedro ,  Jeremy Hatem Tchaicha

IPC分类号： A61K35/17 ,  A61P35/00 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61P35/00 ,  C12N5/0636

摘要： Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.

公开(公告)号：US20240108722A1

公开(公告)日：2024-04-04

申请号：US18261765

申请日：2022-01-18

申请人： Kyle PEDRO ,  James STORER ,  Jan TER MEULEN ,  OBSIDIAN THERAPEUTICS, INC.

发明人： Kyle Pedro ,  James Alexander Storer ,  Jan ter Meulen ,  Rachel Burga ,  Mithun Khattar ,  Michelle Ols ,  Jeremy Tchaicha ,  Shyamsundar Subramanian

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C12N5/0783 ,  C12N15/86

CPC分类号： A61K39/4611 ,  A61K39/4632 ,  A61K39/4644 ,  A61P35/00 ,  C07K14/5443 ,  C12N5/0636 ,  C12N15/86 ,  A61K2039/5156 ,  C12N2501/2321 ,  C12N2501/599 ,  C12N2502/30 ,  C12N2510/00 ,  C12N2740/15043

摘要： Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using arapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.